Zoetis Boosts Diagnostic Momentum with VitalRADS Integration, Strengthening Imaging Services

Zoetis Inc. has strengthened its position in the animal health diagnostics space by completing the acquisition of VitalRADS, a veterinary teleradiology services platform, further advancing its Global Diagnostics portfolio toward a full end‑to‑end Virtual Reference Laboratory.

Finalized in July 2026 during the second quarter, the acquisition brings VitalRADS’ around‑the‑clock teleradiology services—including board‑certified veterinary specialists reviewing digital imaging across radiographs, ECGs, CT scans and MRIs—to Zoetis’ suite of diagnostics offerings. These services are augmented by AI‑assisted report generation and quality‑assurance workflows, plus VitalRADS’ mobile ultrasound services and cloud‑based image storage (VitalPACS). Integration of these capabilities positions Zoetis to deliver more comprehensive diagnostic solutions to veterinary practices globally. The transaction is expected to close fully in Q3 2026, subject to regulatory approval, with financial terms undisclosed.

This strategic move features prominently in Zoetis’ second‑quarter results, in which diagnostics emerged as a key growth driver. Diagnostics revenue rose 12% to $118 million, buoyed by innovations including Vetscan Imagyst, OptiCell, and the newly integrated VitalRADS platform. Management highlighted plans to further enhance diagnostics offerings with the upcoming OmniMax chemistry analyzer.

Diagnostics Gains Offset Broader Companion Animal Headwinds

Zoetis reported mixed Q2 2026 performance, revealing softness in its core U.S. companion animal business, which it attributed to reduced clinic visits and price sensitivity, while livestock and international segments delivered stronger results. However, diagnostics stood out as a bright spot, contributing meaningful revenue growth and reinforcing the company’s diversified business model.

Strategic Synergy and Future Outlook

By integrating VitalRADS, Zoetis enhances its virtual laboratory strategy, blending AI-driven workflows with specialist expertise—a response to growing demand for faster, high‑quality diagnostics in veterinary care. The acquisition complements earlier expansions, such as Zoetis’ 2025 purchase of UK‑based Veterinary Pathology Group and its development of point‑of‑care diagnostic tools like Vetscan Imagyst and OptiCell.

Looking ahead, the inclusion of VitalRADS and the forthcoming OmniMax analyzer equip Zoetis to deliver more robust diagnostic services, aiming to improve clinical decision‑making and operational efficiency for veterinary professionals.

Significance for Investors

Zoetis’s stock (ticker ZTS) was trading at $71.33 as of September 21, 2026, down 1.01% on the day. Investors should watch how the diagnostics segment—now bolstered by VitalRADS integration and AI‑powered solutions—contributes to future revenue growth and margin expansion, especially amid ongoing pressure in companion animal markets. Successful deployment of these technologies could reinforce Zoetis’s leadership in diagnostic innovation and support long‑term earnings resilience.